Sight Sciences to Present at the Upcoming Morgan Stanley Global Healthcare Conference
Sight Sciences (Nasdaq: SGHT), an eyecare technology company, has announced its participation in the upcoming Morgan Stanley Global Healthcare Conference in New York, NY. The company's management is set to present on Wednesday, September 4, 2024, at 1:50 pm PT / 4:50 pm ET.
Sight Sciences focuses on developing and commercializing innovative, interventional technologies to elevate the standard of care in eyecare. Interested parties can access a live and archived webcast of the fireside chat on the "Investors" section of the company's website at investors.sightsciences.com.
Sight Sciences (Nasdaq: SGHT), un'azienda tecnologica nel settore della cura degli occhi, ha annunciato la sua partecipazione alla prossima Morgan Stanley Global Healthcare Conference a New York, NY. La direzione dell'azienda presenterà il mercoledì 4 settembre 2024, alle 13:50 PT / 16:50 ET.
Sight Sciences si concentra sullo sviluppo e la commercializzazione di tecnologie innovative e interventistiche per elevare gli standard di cura nel settore della oftalmologia. Le parti interessate possono accedere a un webcast in diretta e registrato della conversazione sul
Sight Sciences (Nasdaq: SGHT), una empresa de tecnología en el cuidado ocular, ha anunciado su participación en la próxima Conferencia Global de Salud de Morgan Stanley en Nueva York, NY. La gerencia de la compañía presentará el miércoles 4 de septiembre de 2024, a la 1:50 p.m. PT / 4:50 p.m. ET.
Sight Sciences se centra en desarrollar y comercializar tecnologías interventivas innovadoras para elevar el estándar de atención en el cuidado ocular. Las partes interesadas pueden acceder a un webcast en vivo y grabado de la charla en la sección
사이트 사이언스 (Nasdaq: SGHT)는 안구 관리 기술 회사로 뉴욕에서 열리는 모건 스탠리 글로벌 헬스케어 컨퍼런스에 참여한다고 발표했습니다. 회사 경영진은 2024년 9월 4일 수요일, 오후 1:50 PT / 오후 4:50 ET에 발표할 예정입니다.
사이트 사이언스는 안구 관리 표준을 높이기 위해 혁신적이고 개입적인 기술을 개발하고 상용화하는 데 중점을 두고 있습니다. 관심 있는 분들은 회사 웹사이트의
Sight Sciences (Nasdaq: SGHT), une entreprise de technologie dans le domaine des soins oculaires, a annoncé sa participation à la prochaine Conférence Mondiale sur la Santé de Morgan Stanley à New York, NY. La direction de l'entreprise présentera le mercredi 4 septembre 2024, à 13h50 PT / 16h50 ET.
Sight Sciences se concentre sur le développement et la commercialisation de technologies innovantes et interventionnelles pour élever le niveau de soin en ophtalmologie. Les parties intéressées peuvent accéder à un webinaire en direct et archivé de la discussion dans la section
Sight Sciences (Nasdaq: SGHT), ein Technologieunternehmen im Bereich Augenheilkunde, hat seine Teilnahme an der kommenden Morgan Stanley Global Healthcare Conference in New York, NY, angekündigt. Die Geschäftsführung des Unternehmens wird am Mittwoch, den 4. September 2024, um 13:50 Uhr PT / 16:50 Uhr ET präsentieren.
Sight Sciences konzentriert sich auf die Entwicklung und Vermarktung innovativer, interventioneller Technologien, um den Standard in der Augenheilkunde zu erhöhen. Interessierte Parteien können auf der
- None.
- None.
MENLO PARK, Calif., Aug. 20, 2024 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) ("Sight Sciences" or the "Company"), an eyecare technology company focused on developing and commercializing innovative, interventional technologies that elevate the standard of care, today announced that it will present at the upcoming Morgan Stanley Global Healthcare Conference, in New York, NY.
Sight Sciences’ management is scheduled to present on Wednesday, September 4, 2024, at 1:50 pm PT / 4:50 pm ET. Interested parties may access a live and archived webcast of the fireside chat on the “Investors” section of the company’s website at: investors.sightsciences.com.
About Sight Sciences
Sight Sciences is an eyecare technology company focused on developing and commercializing innovative and interventional solutions intended to transform care and improve patients’ lives. Using minimally invasive or non-invasive approaches to target the underlying causes of the world’s most prevalent eye diseases, Sight Sciences seeks to create more effective treatment paradigms that enhance patient care and supplant conventional outdated approaches. The Company’s OMNI® Surgical System is an implant-free glaucoma surgery technology (i) indicated in the United States to reduce intraocular pressure in adult patients with primary open-angle glaucoma; and (ii) CE Marked for the catheterization and transluminal viscodilation of Schlemm’s canal and cutting of the trabecular meshwork to reduce intraocular pressure in adult patients with open-angle glaucoma. Glaucoma is the world’s leading cause of irreversible blindness. The SION® Surgical Instrument is a bladeless, manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork. The Company’s TearCare® System is 510(k) cleared in the United States for the application of localized heat therapy in adult patients with evaporative dry eye disease due to meibomian gland dysfunction (“MGD”), enabling clearance of gland obstructions by physicians to address the leading cause of dry eye disease. Visit www.sightsciences.com for more information.
Sight Sciences, the Sight Sciences logo, TearCare, SmartHub and SmartLids are trademarks of Sight Sciences registered in the United States. OMNI and SION are trademarks of Sight Sciences registered in the United States, European Union and other territories.
© 2024 Sight Sciences. All rights reserved.
Investor contact:
Philip Taylor
Gilmartin Group
415.937.5406
Investor.Relations@Sightsciences.com
Media contact:
pr@SightSciences.com
FAQ
When is Sight Sciences (SGHT) presenting at the Morgan Stanley Global Healthcare Conference?
Where can I watch the webcast of Sight Sciences' (SGHT) presentation at the healthcare conference?
What is the focus of Sight Sciences (SGHT) as a company?
Where is the Morgan Stanley Global Healthcare Conference being held in 2024?
